Deal Library / Pharma BD Deal Intelligence

Gene Therapy Deals

The Pharma Closeout tracks 24 deals, $57.2B in disclosed deal value, 20 with a post-close Outcome Score for Gene Therapy.

Median Critic Score: 79  ·  Median Outcome Score: 63

Best outcome: Johnson & Johnson (Janssen Biotech Inc.) / Legend Biotech Corporation (96)  ·  Weakest outcome: Novartis AG / Gyroscope Therapeutics (23)

All 24 deals

• Johnson & Johnson (Janssen Biotech Inc.) / Legend Biotech Corporation — 2017 · $9.0B · Worked — the deal delivered on its rationale.
• Vertex Pharmaceuticals Inc. / Semma Therapeutics Inc. — 2019 · $950M · Worked — the deal delivered on its rationale.
• Celgene Corporation / Juno Therapeutics Inc. — 2015 · $2.0B · Worked — the deal delivered on its rationale.
• Vertex Pharmaceuticals Inc. / CRISPR Therapeutics AG — 2015 · $2.6B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Legend Biotech Corporation — 2017 · $350M · Worked — the deal delivered on its rationale.
• Novartis AG / Legend Biotech Corporation — 2023 · $1.1B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Prime Medicine Inc. — 2024 · $3.5B · Largely worked — most objectives met.
• Celgene Corporation / Juno Therapeutics Inc. — 2018 · $9.0B · Largely worked — most objectives met.
• Novartis AG / AveXis Inc. — 2018 · $8.7B · Largely worked — most objectives met.
• Astellas Pharma Inc. / Sangamo Therapeutics, Inc. — 2026 · $50M · Largely worked — most objectives met.
• Pfizer Inc. / Beam Therapeutics Inc. — 2022 · $1.4B · Largely worked — most objectives met.
• Roche Holding AG / Sarepta Therapeutics Inc. — 2019 · $1.7B · Largely worked — most objectives met.
• Novartis AG / Voyager Therapeutics Inc. — 2024 · $1.3B · Largely worked — most objectives met.
• Eli Lilly and Company / Sangamo Therapeutics, Inc. — 2026 · $50M · Mixed — partial payoff, real shortfalls.
• Neurocrine Biosciences Inc. / Voyager Therapeutics Inc. — 2019 · $1.9B · Mixed — partial payoff, real shortfalls.
• Bayer AG / Viralgen — 2020 · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Kiadis Pharma NV — 2020 · $359M · Underwhelmed — fell short of the thesis.
• Roche Holding AG / Spark Therapeutics Inc. — 2019 · $4.3B · Did not work — the deal failed to deliver.
• Novartis AG / Gyroscope Therapeutics — 2021 · $1.5B · Did not work — the deal failed to deliver.
• Astellas Pharma Inc. / Audentes Therapeutics — 2019 · $3.0B · Did not work — the deal failed to deliver.
• Eli Lilly and Company / Akouos Inc. — 2022 · $610M
• Thermo Fisher Scientific Inc. / Henogen S.A. (Novasep viral vector business) — 2021 · $875M
• Thermo Fisher Scientific Inc. / Brammer Bio — 2019 · $1.7B
• Catalent, Inc. / Paragon Bioservices, Inc. — 2019 · $1.2B

← Deal Library  ·  Interactive search  ·  How we score deals